antibody - Bioprocess Development Forum

Articles Downstream Downstream Multimedia

October 5, 2024

Quick guide: setting up mAb downstream processes

This one-page visual guide puts techniques, products, and solutions for downstream processes in one place:…

Ross Burns

Articles Upstream

June 27, 2024

Innovations in perfusion bioprocessing

In this study, we present a method for deriving perfusion culture media by leveraging existing…

Ross Burns

Articles Downstream

November 3, 2023

Chromatography processes for the diversified therapeutic antibody pipeline

The diversity of antibody variants in today’s pipeline presents unique challenges for purification and we…

admin-element

Articles

October 20, 2023

As the therapeutic pipeline diversifies, chromatography toolboxes are expanding.

Development beyond traditional monoclonal antibodies (mAbs) is increasing, and today, we see antibody variants...

admin-element

Articles Downstream

May 4, 2023

Developing a HIC Polishing Step for Removal of mAb Aggregates

This article describes the development of a flow-through (FT) polishing step using hydrophobic...

admin-element

Articles Downstream

April 21, 2023

Optimization of a two-step purification method for bispecific antibodies

Bispecific antibodies (bsAbs) have gained increasing interest over recent years because they can...

admin-element

Articles Downstream

February 23, 2023

Protein L affinity resin is ready to move to manufacturing

Although protein L affinity resins have been available for more than a decade, insufficient binding...

admin-element

Downstream Q&A

January 19, 2023

Chromatography for the Diversified Antibody Pipeline

In this video, Eva Heldin, Section Manager of Antibody Application in R&D at Cytiva is…

admin-element

Articles

April 7, 2022

Next-generation protein L chromatography

Use protein L affinity chromatography to capture bispecific antibodies and antibody fragments...

admin-element

Articles Downstream Upstream

September 9, 2021

Antibody Production Workflow

Antibody-based therapies have evolved beyond monoclonal antibodies (mAbs) to include bispecific...

admin-element